Health Longevity Secrets

Latest Episodes:

Your Mitochondria Are Eating You Alive (How to Rebuild Them) | Oct 27, 2026 Oct 27, 2026

Show notes

Inside every one of your cells live tiny ancient bacteria called mitochondria. When they fail, and they fail decades before you feel sick, they drive cancer, Alzheimer's, heart disease and diabetes. Here's how they fail, and how to rebuild them without drugs.

Chapters
00:00 Introduction
00:33 What mitochondria actually are
02:01 The four ways mitochondria fail
03:56 The diseases this explains
05:34 How to rebuild your mitochondria
07:35 The bottom line

Key takeaways
Mitochondria decide whether a cell lives or dies, control inflammation, sense nutrients and regulate hormones.
They fail in four ways: oxidative damage, DNA mutations, dysfunction, and failed cleanup (mitophagy).
Broken mitochondria release DNA fragments that trigger the cGAS-STING pathway and chronic low-grade inflammation.
What rebuilds them: Zone 2 cardio, high-intensity intervals, time-restricted eating, cold and heat, good sleep, and avoiding what poisons them.

Study
Seyfried TN et al. The metabolic theory of cancer. J Bioenerg Biomembr 2025;57:57-83. https://doi.org/10.1007/s10863-025-10059-w

Music: Epidemic Sound.

Watch the video: https://youtu.be/61PbwUZtvt8
Book: Lies I Taught in Medical School https://robertlufkinmd.com/lies/
Substack: https://robertlufkinmd.substack.com/

Robert Lufkin MD | Health Longevity Secrets. For education only, not medical advice.

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Elizabeth Holmes's Blood Test Dream Is Coming True Without Her Oct 20, 2026

Show notes

Elizabeth Holmes went to prison for promising hundreds of blood tests from a single drop of your finger. Some of what she promised is now FDA cleared, and some of it may never be possible at all. With the new documentary You Can See Everything in theaters, Robert Lufkin MD looks at what Theranos promised, what really happened, what is actually FDA cleared in 2026, the physics of a single drop, and which home and finger-stick tests you can trust.
Watch the video: https://youtu.be/CjpbudYdV1I
Sources
- U.S. SEC, Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud (Mar 14, 2018): https://www.sec.gov/newsroom/press-releases/2018-41
- U.S. Attorney's Office, N.D. Cal., U.S. v. Elizabeth Holmes, et al.: https://www.justice.gov/usao-ndca/us-v-elizabeth-holmes-et-al
- DOJ, Elizabeth Holmes Sentenced To More Than 11 Years For Defrauding Theranos Investors (Nov 18, 2022): https://www.justice.gov/usao-ndca/pr/elizabeth-holmes-sentenced-more-11-years-defrauding-theranos-investors-hundreds
- Walgreens, Walgreens Terminates Relationship with Theranos (2016): https://corporate.walgreens.com/news-and-stories/press-releases/2016/walgreens-terminates-relationship-with-theranos-will-be-closing-operations-at-all-40-theranos-wellness-centers-in-arizona/
- AP, Feds ban Theranos CEO Holmes from running lab for 2 years (2016): https://apnews.com/general-news-16add2a7397b47cca3e8bb463e037526
- FDA 510(k) K230391, BD MiniDraw SST (cleared Dec 1, 2023): https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230391.pdf
- FDA 510(k) K230493, BD MiniDraw H&H: https://www.accessdata.fda.gov/cdrh_docs/reviews/K230493.pdf
- FDA 510(k) K221131, Tasso+ (cleared Aug 12, 2022): https://www.accessdata.fda.gov/cdrh_docs/pdf22/K221131.pdf
- FDA, FDA Clears First Over-the-Counter Continuous Glucose Monitor (Mar 5, 2024): https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor
- Bond MM, Richards-Kortum RR. Drop-to-Drop Variation in the Cellular Components of Fingerprick Blood. Am J Clin Pathol 2015;144:885-894: https://doi.org/10.1309/AJCP1L7DKMPCHPEH
- Jacobsen LM et al. Accuracy of Three Commercial Home-Use Hemoglobin A1c Tests. Diabetes Technol Ther 2022;24(11):789-796: https://doi.org/10.1089/dia.2022.0187
- You Can See Everything (A24, 2026), AP coverage: https://apnews.com/article/nathan-fielder-elizabeth-holmes-documentary-film-premiere-cc89d956b120a0f7035d044e4c6bb3d6
Visual credits
- Product images (Part 5): Theranos miniLab, Fig. 2A from Nourse MB et al., Bioeng Transl Med 2018;3(1):58-70, PMC5773944, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), cropped; Tasso+ image: Tasso, Inc. (tassoinc.com); Stelo image: Dexcom (stelo.com); BD MiniDraw image: BD (Becton, Dickinson and Company) press release, Dec 7, 2023. Company images used with credit; trademarks belong to their owners.
- Article card (Part 5): headline and abstract excerpt from Jacobsen LM et al., Diabetes Technol Ther 2022;24(11):789-796, doi:10.1089/dia.2022.0187
- Screen captures of U.S. government pages (SEC, U.S. Department of Justice, FDA press announcement, FDA 510(k) letters K230391 and K221131) are U.S. government works in the public domain.
- Charts, timeline, checklist and the fingertip-drop animation are original graphics by Robert Lufkin MD, drawn from the sources above.
- Film excerpts: You Can See Everything (A24, 2026), dir. Nathan Fielder and Lance Oppenheim. Short clips from the Official Trailer (https://www.youtube.com/watch?v=HvW_N5p1q44) and Official Teaser (https://www.youtube.com/watch?v=GGJSRFWALTI), used for commentary and criticism. Not affiliated with or endorsed by A24 or the filmmakers.
Photo: Max Morse for TechCrunch, CC BY 2.0, via Wikimedia Commons (cropped/edited).
Educational content only. This is not medical advice. Talk with your own healthcare provider before making changes to your health.

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

EXPLAINER: Did Plague Just Escape From a Russian Lab? Oct 13, 2026

Show notes

A young scientist died in a Russian plague lab. Officials deny an accident. Is biowarfare a real threat, or is the bigger risk something else?

Robert Lufkin MD looks at the death of a young lab worker at Russia's Irkutsk anti-plague institute, why Moscow's denials are hard to take at face value, and what Annie Jacobsen's book Biological War: A Scenario gets right and wrong. Untreated pneumonic plague is almost always fatal. The right antibiotics cut deaths sharply. A strain that shrugs off those drugs is the real nightmare. Historically, the bigger risk has been accidents, secrecy, and a slow response, not a deliberate attack.

Chapters:

00:00 — Introduction
00:41 — What Happened at the Irkutsk Plague Lab
01:54 — Why the World Doesn't Take Russia's Word
03:09 — Satellite Images of Russia's Expanding Biolabs
03:25 — Annie Jacobsen's Biological War Scenario
04:48 — Untreated Plague Is Almost Always Fatal
05:31 — Madagascar's Drug-Resistant Plague Strain
05:50 — Lab Accidents Are More Likely Than Attacks
06:29 — The 2019 Fire at Russia's Vector Lab
06:48 — The Takeaway: Chronic Disease Was the Real Risk

Key takeaways:

A young scientist died of pneumonia of unknown origin at a Siberian plague lab. Independent reports alleged a broken tube of live plague. Russian authorities deny a lab accident.
In 1979, spores leaked from a Soviet military bioweapons facility. Moscow blamed bad meat for 13 years.
Satellite images show 10 new buildings and more than 250,000 square feet added at a Russian biological facility since 2022.
Untreated pneumonic plague is almost always fatal. In a CDC review, antibiotics cut deaths to about 17 percent with the right drugs.
In 1995, doctors in Madagascar found a plague strain resistant to every antibiotic then recommended.
Lab accidents, secrecy, and slow response have been the larger historical risk, including a 2019 fire at the Vector lab.
In the COVID data cited here, nearly 95 percent of hospitalized adults already had a chronic condition.

Studies & sources:

Dr. Lufkin's book Lies I Taught in Medical School.

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

EXPLAINER: How To Live To 117 Oct 06, 2026

Show notes

She lived to 117 — and when scientists sequenced everything from her genome to her gut bacteria, they found a paradox that rewrites what aging has to look like. In this episode, Robert Lufkin MD breaks down the landmark multiomics study of Maria Branyas Morera, the world's oldest verified person, published in Cell Reports Medicine (2025) by the Esteller lab. The study mapped her genome, epigenome, proteome, metabolome, and microbiome — and found a body that was simultaneously very old and biologically young.

Chapters:

00:00 — Introduction
00:43 — Who Was Maria Branyas Morera, the World's Oldest Person?
01:18 — The Multiomics Study Published in Cell Reports Medicine
02:03 — The Paradox: Old and Young at the Same Time
02:23 — Epigenetic Clocks: A Biological Age 23 Years Younger
02:51 — Why Her Short Telomeres May Have Protected Her
03:44 — Clean Metabolism: Very Low Triglycerides, High HDL
04:22 — Inflammaging: Why Low Inflammation Is the Real Headline
05:10 — Gut Microbiome, Daily Yogurt, and Bifidobacterium
06:05 — The Longevity Chain: Gut, Inflammation, Metabolism
06:23 — The Honest Caveat: Half Genetics, Half Lifestyle
07:29 — The Takeaway: What Aging Cleanly Really Means

Key takeaways:

Six epigenetic clocks estimated her biological age as much as 23+ years younger than her chronological age
Her telomeres were among the shortest recorded in a healthy person — possibly acting as a brake on tumor growth rather than a death sentence
Her lipid panel was remarkably clean: extremely low VLDL and triglycerides, very high HDL
Systemic inflammation stayed strikingly low — "inflammaging" was turned down
Her gut microbiome was unusually diverse and dominated by Bifidobacterium — she ate about three yogurts a day for the last 20 years of her life
It's an n-of-1 study: roughly half genetics, half lifestyle — but the pattern points upstream to metabolic health

Studies & sources mentioned:

Santos-Pujol et al., Cell Reports Medicine 2025 — The multiomics blueprint of the individual with the most extreme lifespan

Watch the video version on YouTube: https://youtu.be/0TX_E46sAFk

📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/
📰 Substack newsletter: https://robertlufkinmd.substack.com
🌐 Website: https://robertlufkinmd.com

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Ozempic Face: Why Weight Loss Can Make You Look Older | Kay Durairaj MD Sep 29, 2026

Show notes

A facial plastic surgeon reveals the MRI data on "Ozempic face," why repeated masseter Botox can thin the jawbone, and the topical rapamycin resetting skin cells to a 20-year-old phenotype.

In this episode of Health Longevity Secrets, Robert Lufkin MD sits down with Dr. Kay Durairaj, a USC and UCLA-trained facial plastic surgeon bringing evidence-based medicine to the longevity-aesthetics frontier. Old friends from their UCLA head and neck tumor-board days, they dig into the science most aesthetic clinics gloss over: how GLP-1 drugs uniquely strip facial fat, why exosomes and peptides are a "Wild West," the surprising data on retinoids and epigenetic aging, and how collagen biostimulators and topical rapamycin may genuinely rejuvenate skin at the cellular level.

Chapters:

00:00 — Introduction
02:03 — From Head & Neck Cancer Surgery to Longevity Aesthetics
03:04 — Bringing Evidence-Based Medicine to the Aesthetics Wild West
04:06 — Why Aging Should Be Treated as a Disease
06:07 — Ozempic Face: The MRI Data on Facial Fat Loss
09:14 — The Mid-Face Miracle Protocol: Collagen Biostimulators
10:15 — Reversing Ozempic Face After Rapid Weight Loss
11:15 — Exosomes Explained: Real Biology vs Marketing Hype
14:18 — How to Vet Exosome Sourcing, Purity and Shelf Life
16:22 — The Peptide Wild West: BPC-157, SS-31 and FDA-Approved Options
19:28 — N-of-1 Peptide Risks: Angiogenesis and Oncogenes
20:28 — Do Retinoids Accelerate Aging? The MitraBio Epigenetic Data
23:32 — Sculptra and Radiesse: Real Regenerative Science
25:33 — Masseter Botox and Permanent Jawbone Thinning
29:37 — Three Facial Biomarkers of Biological Age
31:38 — Does Lifting Weights Help or Hurt Your Face?
36:48 — Topical Rapamycin: Resetting Fibroblasts to a 20-Year-Old
40:51 — A New Peptide Skin-Longevity Line and Final Advice

Key takeaways:

GLP-1 drugs uniquely attack facial fat — MRI data show roughly 7% midfacial volume loss for every 10 kg of weight lost, primarily from superficial and deep cheek fat pads, driving "Ozempic face."
Collagen biostimulators (like Sculptra and Radiesse) can preserve or restore facial volume during rapid weight loss and have 20+ years and 200+ peer-reviewed papers behind their collagen-remodeling effects.
The exosome and research-peptide markets are largely unregulated — source, purity, shelf life, and donor quality matter, and lyophilized "exosome" skincare is often just protein fragments.
Repeated masseter Botox can thin the mandibular bone, especially in postmenopausal women — animal data are consistent, human data are mixed, so caution is warranted with aggressive long-term use.
Topical rapamycin (a "rapalog") may reset the fibroblast mTOR cycle, shifting aged, bloated skin cells toward a younger, spindle-shaped phenotype — an emerging frontier in cellular skin rejuvenation.

Studies & sources:

Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists (7% loss per 10 kg) — https://pubmed.ncbi.nlm.nih.gov/40407186/
Soft Tissue Facial Changes Following Massive Weight Loss, Aesthetic Surgery Journal Open Forum 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11427949/
MitraBio epigenetic skin DNA-methylation tape-strip profiling — https://mitrabio.tech/resources/unlocking-epigenetic-insights/
Repeated botulinum toxin masseter injections decrease mandibular angle bone volume — https://pmc.ncbi.nlm.nih.gov/articles/PMC5466904/
RapaLogic / Re-Q topical rapalog for fibroblast skin rejuvenation — https://www.rapamycin.news/t/a-new-rapalog-for-skin-aging-rapalogix-health-rlx-201/22010
GHK-Cu copper peptide: regenerative and protective actions in skin — https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
Dr. Kay Durairaj — Beauty by Dr. Kay — https://beautybydrkay.com/

📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

EXPLAINER: Will AI Cure All Disease? Sep 22, 2026

Show notes

Will AI cure all disease? 90% of biomedical papers published in December 2025 show signs of AI assistance — and the Nobel laureate behind AlphaFold says AI could help end all disease within a decade. In this episode, Robert Lufkin MD examines what artificial intelligence is really doing to health science: the quiet takeover of the scientific paper, the first AI-discovered drug to pass a Phase 2a trial, robot laboratories running experiments around the clock, and the honest caveats behind the "end of disease" headlines — plus what it all means for your health today.

Chapters:

00:00 — The 90% Stat: AI Fingerprints in Biomedical Papers
00:49 — Part 1: The Quiet Takeover of the Scientific Paper
02:16 — Part 2: The Wins Are Real
02:46 — AlphaFold, 200 Million Proteins & the 2024 Nobel Prize
03:13 — Rentosertib: First AI-Discovered Drug to Pass Phase 2a
04:02 — The Superbug Puzzle: 10 Years vs 2 Days
04:22 — Part 3: Robot Labs & the 10-Year Promise
05:26 — Demis Hassabis on "The End of Disease"
06:26 — Part 4: The New Bottleneck Is Verification
07:43 — Part 5: The Honest Caveats
08:42 — Part 6: The Takeaway

Key takeaways:

Roughly 90% of biomedical papers published in December 2025 show measurable signs of AI writing assistance — most of it polishing, not fraud.
AlphaFold predicted structures for essentially all 200 million known proteins and earned the 2024 Nobel Prize in Chemistry.
Rentosertib became the first drug with an AI-discovered target and AI-designed molecule to improve lung function in a randomized, placebo-controlled Phase 2a trial (Nature Medicine).
Autonomous "robot labs" like Lila Sciences ($1.3B valuation, backed by Nvidia) aim to run science at machine speed.
The bottleneck in science is shifting from producing findings to verifying them — zero AI-discovered drugs have full FDA approval so far.
No matter how fast discovery gets, your metabolic health remains the foundation AI can't replace.

Studies & sources:

📖 Dr. Lufkin's book "Lies I Taught in Medical School"

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Ultrasound to Calm the Nervous System | Jon Hacker Sep 15, 2026

Show notes

Modern technology is tricking your nervous system into fight-or-flight — and it's decently profitable to keep you there. Jon Hacker, CEO of NeurGear, explains how focused ultrasound vagus nerve stimulation can switch you back.

In this episode of Health Longevity Secrets, Robert Lufkin MD sits down with Jon Hacker, biomedical engineer and CEO/co-founder of NeurGear, the company behind ZenBud — the first ultrasound-based vagus nerve stimulator. They cover how the vagus nerve governs your rest-and-digest state, why so many of us are stuck in survival mode, how ultrasound compares to electrical stimulators, what the clinical trial data shows, and where single-neuron interfaces could take medicine next.

Chapters:

00:00 — Introduction
01:36 — From Anime Dream to Neurotech Startup: Jon Hacker's Story
06:32 — How AI Supercharges a Small Hardware Team
09:26 — Why Ultrasound Won: Two Pivots to the Vagus Nerve
12:21 — Vagus Nerve 101: Rest-and-Digest vs Survival State
14:59 — How Modern Technology Traps You in Fight-or-Flight
16:02 — Measuring Vagal Tone: HRV, Resting Heart Rate & Reaction Time
19:44 — How Focused Ultrasound Activates a Nerve
21:07 — ZenBud vs Electrical Vagus Stimulators (Pulsetto, Truvaga)
23:00 — Dosing ZenBud: 30-Minute Sessions, Sleep & Safety Limits
26:05 — The Medical Industry's Incentive Problem
30:16 — What to Track: Why Quality of Life Beats Biometrics
32:34 — Side Effects & Overuse: Headache Warning Signs
34:22 — Where VNS Fits: Sleep, Diet, Exercise & Breathwork
36:57 — The Future: Single-Neuron Interfaces & Full-Dive VR

Key takeaways:

Your vagus nerve drives your "rest-and-digest" state — low vagal tone leaves you stuck in survival mode, and chronic survival-state activation feeds the chronic diseases we face today
ZenBud uses low-intensity focused ultrasound (not electricity) to stimulate the auricular branch of the vagus nerve — no shocks, no gel pads, no app required
In a 4-week pilot trial, daily 5-minute sessions produced significant reductions in anxiety, depression, and PTSD symptom scores
Reaction time, resting heart rate, and HRV can track nervous-system changes — but your quality of life is the gold standard
Start with 5 minutes a day and scale up slowly; a mild reversible headache is the signal to dial back

Studies & sources:

Kohler I, Hacker J, Martin E — "Reduction of Anxiety-Related Symptoms Using Low-Intensity Focused Ultrasound Neuromodulation" (JMIR Neurotechnology, 2025) — https://neuro.jmir.org/2025/1/e69770
Auricular Ultrasonic Vagus Nerve Stimulation (review, PMC) — https://pmc.ncbi.nlm.nih.gov/articles/PMC12468173/
ZenBud device — https://zenbud.health
NeurGear — https://neurgear.com

📖 Dr. Lufkin's book Lies I Taught in Medical School · 📰 Substack newsletter · 🌐 robertlufkinmd.com

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

EXPLAINER: Will mRNA Vaccines Cure Cancer? Sep 08, 2026

Show notes

For the first time in history, a personalized mRNA cancer vaccine has passed a Phase 3 clinical trial. Robert Lufkin MD breaks down the Moderna/Merck melanoma result, how a vaccine custom-built from your own tumor actually works, the 49% drop in recurrence risk behind the headlines — and the honest answer to whether mRNA vaccines will cure cancer.

In this episode of Health Longevity Secrets, Robert Lufkin MD explains the science of personalized mRNA cancer vaccines: neoantigens, the AI-designed "most wanted poster" for your immune system, the five-year KEYNOTE-942 data, the stunning pancreatic cancer signal from Memorial Sloan Kettering, the BioNTech colorectal trial shutdown that reminds us why we run trials — and what still sits upstream of it all: your metabolic health.

Chapters:

00:00 — Introduction: A Cancer Vaccine Makes History
00:43 — What Just Happened: Moderna/Merck Phase 3 Melanoma Trial
01:44 — A Vaccine Made From Your Own Tumor: How It Works
02:31 — Neoantigens: A "Most Wanted Poster" for Your T-Cells
03:17 — The Numbers Behind the Hype: 49% Lower Recurrence at 5 Years
03:53 — Pancreatic Cancer Vaccine: The Sloan Kettering Survival Signal
04:44 — So Will mRNA Vaccines Cure Cancer? The Honest Answer
05:40 — The Platform Play: Lung, Kidney & Prostate Cancer Trials
06:09 — The Honest Caveats: Press Releases vs Peer Review
06:45 — The Colorectal Trial Shutdown: A Reality Check
07:57 — The Takeaway: Metabolic Health Still Sits Upstream

Key takeaways:

Intismeran autogene + Keytruda is the first mRNA cancer vaccine to succeed in a Phase 3 trial — FDA approval possibly by early 2027.
These are NOT prevention shots — each dose is custom-built from one patient's tumor mutations to hunt residual cancer cells after surgery.
Five-year Phase 2b data (KEYNOTE-942): 49% lower risk of recurrence or death, and 62% lower risk of distant metastasis or death at three years.
Pancreatic trial (n=16): ~90% of immune responders alive 4–6 years after surgery vs ~25% of non-responders — hypothesis-generating, not proof.
The reality check: BioNTech/Genentech halted a colorectal Phase 2 after MORE deaths in the vaccine-alone arm — same technology, different cancer, opposite result.
The Phase 3 result is a top-line press release, not yet peer-reviewed; the vaccine is not FDA-approved and is only available in clinical trials today.
Muscle, blood sugar control, sleep, not smoking, and sun protection remain the most proven cancer-risk tools you own right now.

Studies & sources:

Dr. Lufkin's book Lies I Taught in Medical School — more at robertlufkinmd.com and the Health Longevity Brief on Substack.

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

The Alzheimer's Lie: It's Not The Amyloid | David Perlmutter MD Sep 01, 2026

Show notes

Neurologist David Perlmutter MD says the beta-amyloid theory of Alzheimer's is wrong — and the real culprit is your brain's own immune cells. In this episode of Health Longevity Secrets, Robert Lufkin MD sits down with the #1 New York Times bestselling author to unpack his new book Brain Defenders: how diet, blood sugar, and metabolic health flip the brain's microglia from protective to destructive, why anti-amyloid drugs offer "trivial" benefit, and which biomarkers actually predict your brain's future.

Chapters:

00:00 — Introduction
01:38 — Why He Left Mainstream Neurology to Prevent Brain Decline
05:24 — Building the World's Largest Integrative Neurology Practice
06:55 — The Common Pathway From Metabolism to Brain Degeneration
08:25 — Why the Beta-Amyloid Theory of Alzheimer's Is Wrong
09:11 — What Are Microglia? The Brain's Immune Cells (M1 vs M2)
12:13 — From Brain "Glue" to Master Regulators of Your Synapses
16:00 — How Body Inflammation and Cytokines Reach the Brain
18:15 — Leaky Gut, the Microbiome, and Brain Degeneration
19:46 — Ultra-Processed Foods Raise Alzheimer's Risk Up to 270%
25:02 — Synaptic Pruning: The Link Between Autism, ADHD and Alzheimer's
29:36 — Why Diabetics Recover Worse From Head Trauma
31:51 — Anti-Amyloid Drugs: "Trivial" Benefit, Serious Harm
35:37 — The Biomarkers to Track: Fasting Glucose, Insulin, A1C
40:09 — On the Horizon: Mitochondrial Therapies and Microglial Transplants
45:26 — Glyphosate, Air Pollution and 40Hz Light Therapy
47:00 — Brain Defenders Releases August 18 — Final Takeaways

Key takeaways:

Alzheimer's is increasingly understood as a "synaptopathy" — a disease of lost synapses driven by the brain's own immune cells (microglia), not simply beta-amyloid plaque.
Microglia shift from supportive (M2) to destructive (M1) in response to metabolic signals: high blood sugar, insulin resistance, elevated blood pressure, excess body fat, and inflammation.
A long-term cohort found each daily serving of ultra-processed food raised Alzheimer's risk ~13%, with 10+ servings/day linked to a 2.7-fold (270%) increase.
A Cochrane review of anti-amyloid antibodies found "trivial" cognitive benefit alongside meaningful harm, including brain swelling and microbleeds (ARIA).
The most actionable brain biomarkers are cheap and accessible: fasting glucose, fasting insulin, A1c, waist circumference, and a continuous glucose monitor — aim for optimal, not just "normal."
Emerging frontiers target the mitochondria inside microglia — metformin, CoQ10, urolithin A, exercise, fasting, ketones, and 40Hz gamma light therapy.

Studies & sources:

Weinstein et al., J Prev Alzheimers Dis — ultra-processed food and Alzheimer's risk
Cochrane Review (2026) — anti-amyloid monoclonal antibodies for Alzheimer's
Iaccarino, Tsai et al. (Tsai Lab, MIT) — 40Hz gamma light and microglia

Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

EXPLAINER: Human Age Reversal Has Begun Aug 25, 2026

Show notes

They just injected youth genes into a human eye. On June 9, 2026, a patient with glaucoma became the first human ever dosed with ER-100 — an epigenetic reprogramming gene therapy designed not just to slow aging, but to reverse it. In this solo explainer, Dr. Robert Lufkin breaks down the science of partial cellular reprogramming, the Harvard study that restored vision in old mice, the built-in genetic safety switch, and what this first-in-human trial really means — and doesn't mean — for the future of longevity.

Chapters

00:00 — Introduction: Youth Genes Injected Into a Human Eye
00:41 — Glaucoma: Blindness That Only Moves in One Direction
01:42 — The Harvard Mice That Got Their Vision Back
02:05 — Yamanaka Factors and the OSK Gene Cocktail
03:08 — June 9, 2026: First Human Dosed With ER-100
03:54 — The Doxycycline Safety Switch Built Into the Genes
04:35 — Aging as Lost Information: Hardware vs Software
05:27 — Why Scientists Chose the Eye First
06:05 — The Honest Caveat: Phase 1 Means Safety, Not Efficacy
07:13 — The Takeaway: What Already Works for Longevity

Studies & sources mentioned

Lu et al. 2020, Nature — OSK reprogramming restored vision in old mice: https://pubmed.ncbi.nlm.nih.gov/33268865/
Tham et al. 2014, Ophthalmology — global glaucoma prevalence: https://pubmed.ncbi.nlm.nih.gov/24974815/
Life Biosciences — first patient dosed in Phase 1 trial of ER-100: https://www.globenewswire.com/news-release/2026/06/09/3308634/0/en/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies.html
Trial registration (NCT07290244): https://clinicaltrials.gov/study/NCT07290244

⚠️ Honest caveat: this is a Phase 1, open-label safety trial in roughly 18 adults. The primary endpoint is safety and tolerability — not vision restoration. Nothing here is medical advice; this content is for educational purposes only.

📕 Book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/
📰 Weekly newsletter: https://robertlufkinmd.substack.com
🌐 Website: https://robertlufkinmd.com

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com

Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected